Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Schizophrenia News

a doctor and patient sit on couches talking
News
aLAIs a Useful Treatment Option for Schizophrenia, Study Results Underscore
01/05/2024
Brionna Mendoza
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable...
01/05/2024
Psych Congress Network
Female Soldier or Veteran
News
Pharmacotherapy Suboptimal After Schizophrenia Diagnosis in VHA System
12/12/2023
Julie Gould
Study indicates deficiencies in pharmacotherapy practices following schizophrenia diagnosis and underscores the substantial impact of the condition on veterans' hospitalization rates, health care resource utilization (HRU), and associated...
Study indicates deficiencies in pharmacotherapy practices following schizophrenia diagnosis and underscores the substantial impact of the condition on veterans' hospitalization rates, health care resource utilization (HRU), and associated...
Study indicates deficiencies in...
12/12/2023
Psych Congress Network

Advertisement

Stock Doctor
News
Experts Guide Aripiprazole Lauroxil Use for Tailored Schizophrenia Treatment
12/01/2023
A poster recently presented at NEI Congress 2023 suggests the use of aripiprazole lauroxil (AL), an LAI atypical antipsychotic for schizophrenia, as a versatile option supported by its pharmacokinetic, efficacy, and safety characteristics.
A poster recently presented at NEI Congress 2023 suggests the use of aripiprazole lauroxil (AL), an LAI atypical antipsychotic for schizophrenia, as a versatile option supported by its pharmacokinetic, efficacy, and safety characteristics.
A poster recently presented at...
12/01/2023
Psych Congress Network
brain stock image
News
Abnormal Experience of Positive Stimuli a Possible Intervention Target in Schizophrenia
11/27/2023
Jolynn Tumolo
People with schizophrenia and people at risk for psychosis experience pleasant and negative stimuli differently than healthy controls, meta-analysis find.
People with schizophrenia and people at risk for psychosis experience pleasant and negative stimuli differently than healthy controls, meta-analysis find.
People with schizophrenia and...
11/27/2023
Psych Congress Network
Add-on N-acetyl-cysteine, Polyunsaturated Fatty Acids May Benefit Patients With Schizophrenia
News
Add-on N-acetyl-cysteine, Polyunsaturated Fatty Acids May Benefit Patients With Schizophrenia
11/20/2023
Jolynn Tumolo
Adjunctive N-acetyl-cysteine and polyunsaturated fatty acids can be provisionally recommended for improving negative symptoms, general psychopathology, and possibly cognition in patients with schizophrenia, according to a systematic umbrella...
Adjunctive N-acetyl-cysteine and polyunsaturated fatty acids can be provisionally recommended for improving negative symptoms, general psychopathology, and possibly cognition in patients with schizophrenia, according to a systematic umbrella...
Adjunctive N-acetyl-cysteine and...
11/20/2023
Psych Congress Network

Advertisement

stock brain image
News
Blonanserin Similar Efficacy to Risperidone for Schizophrenia, but Side Effects Differ
11/06/2023
Jolynn Tumolo
The efficacy of blonanserin, a second-generation antipsychotic approved for the treatment of schizophrenia in Japan, South Korea, and China, is similar to that of risperidone, although the medications differ in terms of adverse events.
The efficacy of blonanserin, a second-generation antipsychotic approved for the treatment of schizophrenia in Japan, South Korea, and China, is similar to that of risperidone, although the medications differ in terms of adverse events.
The efficacy of blonanserin, a...
11/06/2023
Psych Congress Network
schizophrenia treatment
News
TV-46000 Demonstrates Prolonged Schizophrenia Relapse Prevention, SHINE Study Finds
10/25/2023
Meagan Thistle
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting subcutaneous antipsychotic (LASCA), exhibits a favorable long-term benefit-risk profile for patients with schizophrenia, according to study results presented in a poster at Psych Congress 2023.
TV-46000, a long-acting...
10/25/2023
Psych Congress Network
Researchers Identify Correlation Between Schizophrenia and Somatic Mutations
News
Researchers Identify Correlation Between Schizophrenia and Somatic Mutations
10/18/2023
Tom Valentino, Digital Managing Editor
A correlation between schizophrenia and somatic copy-number variants—a type of mutation that occurs early in development, but after genetic material is inherited—has been identified by Harvard Medical Institute researchers.
A correlation between schizophrenia and somatic copy-number variants—a type of mutation that occurs early in development, but after genetic material is inherited—has been identified by Harvard Medical Institute researchers.
A correlation between...
10/18/2023
Psych Congress Network

Advertisement

New Study Identifies Genetic Variances Linked to Schizophrenia
News
New Study Identifies Genetic Variances Linked to Schizophrenia
10/11/2023
Tom Valentino, Digital Managing Editor
Scientists from the University of North Carolina School of Medicine have published a study seeking to advance the genetic basis of schizophrenia by identifying the genetic variances that have a causal effect in development. 
Scientists from the University of North Carolina School of Medicine have published a study seeking to advance the genetic basis of schizophrenia by identifying the genetic variances that have a causal effect in development. 
Scientists from the University...
10/11/2023
Psych Congress Network
Digital Therapeutic Improves Negative Symptoms of Schizophrenia
News
Digital Therapeutic Improves Negative Symptoms of Schizophrenia
10/03/2023
Evi Arthur
Digital therapeutics have the potential to reduce experiential negative symptoms (ENS) in patients with schizophrenia, according to poster findings presented at Psych Congress 2023 in Nashville, Tennessee.
Digital therapeutics have the potential to reduce experiential negative symptoms (ENS) in patients with schizophrenia, according to poster findings presented at Psych Congress 2023 in Nashville, Tennessee.
Digital therapeutics have the...
10/03/2023
Psych Congress Network

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use